Biogen, Denali to halt late-stage trial for Parkinson’s disease drug
IvelinRadkov/iStock via Getty Images


Denali Therapeutics (NASDAQ:DNLI) announced Monday that the company and its partner Biogen (NASDAQ:BIIB) have decided to discontinue a Phase 3 trial for Parkinsonâs disease (PD) candidate BIIB122 (DNL151).
The company said the decision follows a review of its portfolio timelines and existing resources. In a regulatory filing, Denali (DNLI) emphasized that the changes are not based on any safety or efficacy concerns related to BIIB122.

In line with a collaboration, Denali (DNLI) and Biogen (BIIB) were advancing BIIB122 in two global late-stage clinical trials: Phase 2b LUMA study targeted at early-stage PD and Phase 3 LIGHTHOUSE study for PD-related to LRRK2 mutations.
The companies said that patients already enrolled in the LIGHTHOUSE trial could join the LUMA study, which, as part of the review, has also been modified to include PD patients with LRRK2 mutations.


More on Denali

Biogen licenses amyloid beta-related program from Denali
Denali Therapeutics: Pioneering The Neurodegenerative Space With Blood-Brain Barrier Innovations